Riskpilot← Back to searchSign inGet full accessDecem ENT Oy
OYDissolvedY-tunnus 3202457-6C/O Decem Pharma Oy Pakkalankuja 6Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2021— employees
Revenue 2022
EUR 451K
EBITDA margin
49.2%
Equity ratio
98.9%
Financial strength
Net profit 2022
EUR 177K
| Revenue | EUR 451K | — |
| EBITDA | EUR 222K | — |
| Net profit | EUR 177K | — |
| Total assets | EUR 1,1M | — |
| Equity | EUR 1,1M | — |
| Employees | — | — |
Legal name
Decem ENT Oy
Y-tunnus number
3202457-6
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
31. maaliskuuta 2021
Share capital
EUR 0
Employees
—
VAT registered
No
Audit selected
No
Last report
2022-11-30
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on lääkkeiden, rohdosvalmisteiden, ravintolisien ja yleisten kauppatavaroiden valmistaminen, maahantuonti sekä myynti ja markkinointi. Yhtiö voi myös sopimusvalmistuttaa tuotteita. Yhtiö tekee tutkimuksia, se voi omistaa ja hallita irtainta ja kiinteää omaisuutta, oikeuksia, osuuksia ja arvopapereita sekä käydä niillä kauppaa. Yhtiö voi harjoittaa tuonti-, vienti- ja agentuuritoimintaa.
Address
C/O Decem Pharma Oy Pakkalankuja 6
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 |
|---|---|
| Revenue | 451 |
| Staff expenses | −1 |
| EBITDA | 222 |
| Depreciation & amort. | — |
| EBIT | 222 |
| Net financials | 0 |
| Profit before tax | 222 |
| Tax | 44 |
| Net profit | 177 |
| Item | 2022 |
|---|---|
| Total assets | 1 096 |
| Equity | 1 084 |
| Long-term debt | — |
| Short-term debt | 12 |
| Total debt | 12 |
EBITDA margin
49.2%
This company
15.8%
Market median
+211% vs market
20222022
Equity ratio
98.9%
This company
38.2%
Market median
+159% vs market
20222022
Return on equity
16.4%
This company
18.4%
Market median
+11% vs market
20222022
Net profit margin
39.4%
This company
8.1%
Market median
+386% vs market
20222022
Asset turnover
0.41×
This company
1.12×
Market median
-63% vs market
20222022
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20222022
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
TJ Audit | Audit | 2021 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2021 | |
| Chairperson | 2021 | |
| Former (1) | ||
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Decem ENT Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Turo Juhani Koila | Audit | 0 companies |
| Tero Tapani Weckroth | Board of Directors | 0 companies |
| Jacob Christoffer Calmvik | Board of Directors | 0 companies |
| Tero Olavi Purra | Board of Directors | 0 companies |
| Erno Johannes Lehtovirta | Chairperson | 0 companies |